Wexford Capital LP Gilead Sciences, Inc. Transaction History

Wexford Capital LP

5 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2022 Feb 14, 2023	BUY	$62.32 - $89.47 $364,634 - $523,488	5,851 New	5,851 $502,000
Q1 2021 May 13, 2021	SELL	$60.0 - $68.46 $30,000 - $34,230	-500 Closed	0 $0
Q3 2020 Nov 16, 2020	SELL	$62.1 - $78.08 $279,450 - $351,360	-4,500 Reduced 90.0%	500 $32,000
Q2 2020 Aug 13, 2020	SELL	$72.34 - $84.0 $6.02 Million - $7 Million	-83,283 Reduced 94.34%	5,000 $385,000
Q1 2020 May 18, 2020	BUY	$62.63 - $80.22 $5.53 Million - $7.08 Million	88,283 New	88,283 $6.6 Million

1,893

1.02B

12M

9.04M

Ticker GILD
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—General
Shares Outstandng 1,253,369,984
Market Cap $110B
Description
Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, and Atripla products for the treatment of HIV/AIDS; Veklury, a...

Get notified when there are updates to the investment portfolio of Wexford Capital LP, based on Form 13F filings with the SEC.

Stay updated on Wexford Capital LP with notifications on news.